Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant-Reference-Cited by-同舟云学术

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant

Published:2015-10-08 Issue:4 Volume:57 Page:973-976
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Jimenez-Zepeda Victor H.,Duggan Peter,Neri Paola,Chaudhry Ahsan,Murray Karen,Culham Marcia,Luider Joanne,Fourie Thomas,Rashid-Kolvear Fariborz,Bahlis Nizar J

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1085534

Reference15 articles.

1. Complete response after autologous stem cell transplant in multiple myeloma

2. The role of complete response in multiple myeloma

3. Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients

4. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients

5. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study;Blood;2022-05-05

2. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma;Hematological Oncology;2020-07-29

3. Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients;Leukemia & Lymphoma;2020-01-06

4. Hematopoietic Stem Cell Transplantation for Multiple Myeloma;Seminars in Oncology Nursing;2017-08

5. VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma;OncoTargets and Therapy;2017-01